Drug treatment of heart failure in the elderly

被引:3
作者
Berliner, D. [1 ]
Bauersachs, J. [1 ]
机构
[1] Hannover Med Sch, Dept Cardiol & Angiol, Carl Neuberg Str 1, D-30625 Hannover, Germany
关键词
Heart failure; Treatment; Aged; Comorbidity; Drug interactions; HOSPITAL ADMISSION; PRIMARY-CARE; HIGH-RISK; MORTALITY; DIAGNOSIS; EFFICACY; DIGOXIN; SAFETY; AGE; INSIGHTS;
D O I
10.1007/s00059-017-4668-9
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The prevalence of heart failure increases with age. Changes in the age distribution and growing life expectancy will lead to a further rise. However, data concerning drug treatment of heart failure especially in the elderly are scarce. Subgroup analyses of the heart failure trials suggest that drug therapy in older patients should follow the recommendations in the current guidelines. In doing so, several common comorbidities in these patients (e. g., impaired renal function) have to be considered and may have an influence on the therapy (e. g., drug dose, choice of active pharmaceutical ingredient, etc.). Especially in old, multimorbid patients, possible interaction of drugs might play a substantial role. In many cases the main goal of the therapy, especially in the very elderly, is to improve symptoms and quality of life.
引用
收藏
页码:207 / 213
页数:7
相关论文
共 40 条
  • [1] Dose response characterization of the association of serum digoxin concentration with mortality outcomes in the Digitalis Investigation Group trial
    Adams, Kirkwood F., Jr.
    Butler, Javed
    Patterson, J. Herbert
    Stough, Wendy Gattis
    Bauman, Jerry L.
    van Veldhuisen, Dirk J.
    Schwartz, Todd A.
    Sabbah, Hani
    Mackowiak, John I.
    Ventura, Hector O.
    Ghali, Jalal K.
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2016, 18 (08) : 1072 - 1081
  • [2] Angermann CE, 2009, EUR J HEART FAIL S, V8, pi5, DOI DOI 10.1093/EURJHF/HFP009
  • [3] Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006: Diagnosis and management
    Arnold, JMO
    Liu, P
    Demers, C
    Dorian, P
    Giannetti, N
    Haddad, H
    Heckman, GA
    Howlett, JG
    Ignaszewski, A
    Johnstone, DE
    Jong, P
    McKelvie, RS
    Moe, GW
    Parker, JD
    Rao, V
    Ross, HJ
    Sequeira, EJ
    Svendsen, AM
    Teo, K
    Tsuyuki, RT
    White, M
    [J]. CANADIAN JOURNAL OF CARDIOLOGY, 2006, 22 (01) : 23 - 45
  • [4] Treatment of Heart Failure with Abnormal Left Ventricular Systolic Function in Older Adults
    Aronow, Wilbert S.
    [J]. HEART FAILURE CLINICS, 2017, 13 (03) : 467 - +
  • [5] Assumption versus evidence: the case of digoxin in atrial fibrillation and heart failure
    Bavendiek, Udo
    Davila, Lukas Aguirre
    Koch, Armin
    Bauersachs, Johann
    [J]. EUROPEAN HEART JOURNAL, 2017, 38 (27) : 2095 - 2099
  • [6] Berliner D, 2009, HERZ, V34, P581, DOI 10.1007/s00059-009-3314-6
  • [7] Digoxin Reduces 30-day All-cause Hospital Admission in Older Patients with Chronic Systolic Heart Failure
    Bourge, Robert C.
    Fleg, Jerome L.
    Fonarow, Gregg C.
    Cleland, John G. F.
    McMurray, John J. V.
    van Veldhuisen, Dirk J.
    Gheorghiade, Mihai
    Patel, Kanan
    Aban, Inmaculada B.
    Allman, Richard M.
    White-Williams, Connie
    White, Michel
    Filippatos, Gerasimos S.
    Anker, Stefan D.
    Ahmed, Ali
    [J]. AMERICAN JOURNAL OF MEDICINE, 2013, 126 (08) : 701 - 708
  • [8] Biomarkers in heart failure
    Braunwald, Eugene
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (20) : 2148 - 2159
  • [9] Chakeabarti S, 2010, J CARD FAIL, V16, pS53, DOI 10.1016/j.cardfail.2010.04.004
  • [10] LCZ696 (Sacubitril/Valsartan) Can We Predict Who Will Benefit?
    Dec, G. William
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2015, 66 (19) : 2072 - 2074